For retail sale medicaments with insulin or hormones or antibiotics market in Sweden

Earlier Report Observations

From 2018, the Swedish market for retail-packed insulin, hormone, and antibiotic medicaments underwent changes as the pharmacy sector opened to non-state players, enhancing competition and accessibility. The 2019 introduction of the 'product of the month' system required pharmacies to offer the cheapest generic alternatives within each pack-size group, promoting price competition. The COVID-19 pandemic in 2020 caused supply chain disruptions and shortages of certain medicines, affecting imports and availability.

In 2021, the number of approved medicinal products increased by 234, broadening the range and contributing to a rise in domestic market size to 357 million USD. However, 2022 saw a over 50% increase in reported drug shortages, primarily due to manufacturing issues, which pressured supply amid continued global supply chain challenges.

By 2023, drug approval processes were streamlined, and the use of digital prescriptions and e-commerce expanded, improving distribution. By 2024, production rebounded to 1,590 million USD, and the market size reached 377 million USD, reflecting sustained domestic demand despite external pressures.

Production for retail sale medicaments with insulin or hormones or antibiotics in Sweden

In value, 2017-2020, M $ US

Annual dynamics of production in Sweden in value, 2017-2020, M $ US

Exports for retail sale medicaments with insulin or hormones or antibiotics from Sweden

Exports in kind, t

After two years of growth, Sweden's exports of retail sale medicaments containing insulin, hormones, or antibiotics declined. In 2020, Sweden exported 6 009 tonnes of these products, marking a gradual decrease of 3.2% from 2019. Over the 2017-2020 period, exports overall increased by 12.2%, with a compound annual growth rate of 3.9%. The peak volume was recorded in 2019 at 6 206 tonnes, which also saw the largest annual increase of 10.4%.

Annual dynamics of product's exports from Sweden in kind, 2017-2020, t

From 2017 to 2020, China, Japan, and Russia were significant buyers of Sweden's retail sale medicaments with insulin, hormones, or antibiotics, accounting for 13.6%, 7.7%, and 7.5% of exports in kind, respectively. However, their combined share reached only 28.9% of total exports, with the remaining 71.1% distributed among numerous other trading partners.

Structure of product's exports in kind by countries, 2017-2020

World map of product's exports from Sweden in kind, 2017-2020

Exports in value, M $ US

In 2020, Sweden exported 1 489 million US dollars worth of retail sale medicaments containing insulin, hormones, or antibiotics, representing a decline of 4.9% compared to 2019. Between 2017 and 2020, exports decreased by 8.4%, equating to an annualized rate of 2.9%. The largest decline occurred in 2018 at 5.1%, while the largest increase was recorded in 2019 at 1.5%.

Annual dynamics of product's exports from Sweden in value, 2017-2020, M $ US

During the 2017-2020 period, China, France, and the United States were key buyers of Sweden's retail sale medicaments with insulin, hormones, or antibiotics in value terms, contributing 12.7%, 10.2%, and 8.9% of exports, respectively. Their combined share amounted to 31.8% of total exports, with the remaining 68.2% spread across many other partners.

Structure of product's exports in value by countries, 2017-2020

World map of product's exports from Sweden in value, 2017-2020

Imports for retail sale medicaments with insulin or hormones or antibiotics to Sweden

Imports in kind, t

Sweden imported approximately 953 tonnes of retail sale medicaments with insulin, hormones, or antibiotics in 2020, showing minimal change from the previous year. Over the 2017-2020 period, imports increased by 3.8%, with an annualized rate of 1.2%. The lowest volume was recorded in 2018 at 861 tonnes, while the peak was in 2019 at 956 tonnes. The largest decline occurred in 2018 at 6.2%, and the largest increase was in 2019 at 11.1%.

Annual dynamics of product's imports to Sweden in kind, 2017-2020, t

From 2017 to 2020, Denmark, Germany, and France were the three principal sources for Sweden's imports in kind of retail sale medicaments containing insulin, hormones, or antibiotics, together accounting for 68.1% of total imports.

Structure of product's imports in kind by countries, 2017-2020

World map of product's imports to Sweden in kind, 2017-2020

Imports in value, M $ US

Following a two-year uptick, Sweden's imports of retail sale medicaments with insulin, hormones, or antibiotics declined. In 2020, imports amounted to 268 million US dollars, which is 4.4% lower year-over-year. Over the 2017-2020 period, imports increased by 9.1%, with a compound annual growth rate of 2.9%. The highest value was recorded in 2019 at 281 million US dollars, and the largest increase occurred in 2018 at 10.1%.

Annual dynamics of product's imports to Sweden in value, 2017-2020, M $ US

In the 2017-2020 period, Denmark, France, and Belgium consistently served as the main sources for Sweden's imports in value terms of retail sale medicaments with insulin, hormones, or antibiotics, accounting for 42.1%, 14.1%, and 12.5% of imports, respectively. Together, they represented 68.7% of total import flows.

Structure of product's imports in value by countries, 2017-2020

World map of product's imports to Sweden in value, 2017-2020